New clinical trials of monoclonal antibodies (mAb), have grown 115% globally over the ten year period 2007-2016 according to GlobalData, a leading data and analytics company. The most prominent increase, 26%, occurred in 2015.

The company tracks clinical trials activity across the world and has identified 5,273 industry mAb clinical trials with a start date between January 1, 2007, and December 31, 2016.

A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively. Overall, Phase II trials outnumbered all other trials by contributing between 31% and 46% across the period.

A spokesperson from the GlobalData Pharma analyst team commented: 'The share of Phase I trials started at 18% in 2007 and increased to 27% by 2016. Phase III trials' contribution remained flat at an average of 24% across the 10-year period, whereas Phase IV trials decreased in share from 13% to 12% in the first and last years, respectively.'

GlobalData plc published this content on 26 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 October 2017 11:34:17 UTC.

Original documenthttps://www.globaldata.com/new-clinical-trials-monoclonal-antibodies-grown-115-last-ten-years/

Public permalinkhttp://www.publicnow.com/view/D78272DEAEFF2E1110442D59CA29C92F7A6EF97F